Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Scientists discovered two genes involved in hyperemesis gravidarum, a condition that can cause extreme nausea and vomiting ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... expanding into polygenic disorders such as diabetes. Synthetic biology is also projected to experience ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

While most students spend their January break catching up on well-deserved sleep or binge-watching Netflix, 20-year-old Ruby ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... cell disease and beta-thalassemia—expanding into polygenic disorders such as diabetes. Synthetic biology is also ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Sanofi and Regeneron’s once close relationship has ... refocus Sanofi since taking the helm – for example axing R&D in diabetes, once its cash-cow category, and cardiovascular – in order ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.

AZ and Regeneron will collaborate on finding small ... which puts the programme firmly in AZ's wheelhouse given its focus on diabetes with drugs like its blockbuster SGLT2 inhibitor Farxiga ...